These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 28440492)

  • 1. AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier.
    Seike M; Kim CH; Zou F; Noro R; Chiba M; Ishikawa A; Κunugi S; Kubota K; Gemma A
    Oncol Rep; 2017 Jun; 37(6):3261-3269. PubMed ID: 28440492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients.
    Ishikawa M; Sonobe M; Nakayama E; Kobayashi M; Kikuchi R; Kitamura J; Imamura N; Date H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3(Suppl 3):S467-76. PubMed ID: 23242819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer.
    Nonagase Y; Takeda M; Azuma K; Hayashi H; Haratani K; Tanaka K; Yonesaka K; Ishii H; Hoshino T; Nakagawa K
    Thorac Cancer; 2019 Oct; 10(10):1928-1935. PubMed ID: 31419057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gas6 derived from cancer-associated fibroblasts promotes migration of Axl-expressing lung cancer cells during chemotherapy.
    Kanzaki R; Naito H; Kise K; Takara K; Eino D; Minami M; Shintani Y; Funaki S; Kawamura T; Kimura T; Okumura M; Takakura N
    Sci Rep; 2017 Sep; 7(1):10613. PubMed ID: 28878389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
    Zhang Z; Lee JC; Lin L; Olivas V; Au V; LaFramboise T; Abdel-Rahman M; Wang X; Levine AD; Rho JK; Choi YJ; Choi CM; Kim SW; Jang SJ; Park YS; Kim WS; Lee DH; Lee JS; Miller VA; Arcila M; Ladanyi M; Moonsamy P; Sawyers C; Boggon TJ; Ma PC; Costa C; Taron M; Rosell R; Halmos B; Bivona TG
    Nat Genet; 2012 Jul; 44(8):852-60. PubMed ID: 22751098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance.
    Xiong R; Sun XX; Wu HR; Xu GW; Wang GX; Sun XH; Xu MQ; Xie MR
    Thorac Cancer; 2020 Jan; 11(1):156-165. PubMed ID: 31777195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.
    Karachaliou N; Chaib I; Cardona AF; Berenguer J; Bracht JWP; Yang J; Cai X; Wang Z; Hu C; Drozdowskyj A; Servat CC; Servat JC; Ito M; Attili I; Aldeguer E; Capitan AG; Rodriguez J; Rojas L; Viteri S; Molina-Vila MA; Ou SI; Okada M; Mok TS; Bivona TG; Ono M; Cui J; Ramón Y Cajal S; Frias A; Cao P; Rosell R
    EBioMedicine; 2018 Mar; 29():112-127. PubMed ID: 29433983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
    Taniguchi H; Yamada T; Wang R; Tanimura K; Adachi Y; Nishiyama A; Tanimoto A; Takeuchi S; Araujo LH; Boroni M; Yoshimura A; Shiotsu S; Matsumoto I; Watanabe S; Kikuchi T; Miura S; Tanaka H; Kitazaki T; Yamaguchi H; Mukae H; Uchino J; Uehara H; Takayama K; Yano S
    Nat Commun; 2019 Jan; 10(1):259. PubMed ID: 30651547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AXL-GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases.
    Wu X; Ma W; Zhou Q; Yan H; Lim ZF; Huang M; Deng C; Yu X; Su H; Komo S; Yang H; Zhang X; Wen S; Zhang Z; Ma PC
    J Cancer Res Clin Oncol; 2017 Oct; 143(10):1947-1957. PubMed ID: 28551766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer.
    Liu YN; Tsai MF; Wu SG; Chang TH; Tsai TH; Gow CH; Chang YL; Shih JY
    Int J Cancer; 2019 Sep; 145(6):1609-1624. PubMed ID: 31162839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma.
    Song X; Wang H; Logsdon CD; Rashid A; Fleming JB; Abbruzzese JL; Gomez HF; Evans DB; Wang H
    Cancer; 2011 Feb; 117(4):734-43. PubMed ID: 20922806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gas6 expression and Tyrosine kinase Axl Sky receptors: Their relation with tumor stage and grade in patients with bladder cancer.
    Akgül M; Baykan Ö; Çağman Z; Özyürek M; Tinay İ; Akbal C; Uras F; Türkeri L
    Arch Ital Urol Androl; 2021 Jun; 93(2):148-152. PubMed ID: 34286546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coexpression of receptor tyrosine kinase AXL and EGFR in human primary lung adenocarcinomas.
    Wu Z; Bai F; Fan L; Pang W; Han R; Wang J; Liu Y; Yan X; Duan H; Xing L
    Hum Pathol; 2015 Dec; 46(12):1935-44. PubMed ID: 26475093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas.
    Tsukita Y; Fujino N; Miyauchi E; Saito R; Fujishima F; Itakura K; Kyogoku Y; Okutomo K; Yamada M; Okazaki T; Sugiura H; Inoue A; Okada Y; Ichinose M
    Mol Cancer; 2019 Feb; 18(1):24. PubMed ID: 30744655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.
    Kim D; Bach DH; Fan YH; Luu TT; Hong JY; Park HJ; Lee SK
    Cell Death Dis; 2019 May; 10(5):361. PubMed ID: 31043587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AXL and acquired resistance to EGFR inhibitors.
    Postel-Vinay S; Ashworth A
    Nat Genet; 2012 Jul; 44(8):835-6. PubMed ID: 22836088
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.
    Wu F; Li J; Jang C; Wang J; Xiong J
    Int J Clin Exp Pathol; 2014; 7(10):6653-61. PubMed ID: 25400744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
    Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
    BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship Between Increased Expression of the Axl/Gas6 Signal Cascade and Prognosis of Patients with Upper Tract Urothelial Carcinoma.
    Hattori S; Kikuchi E; Kosaka T; Miyazaki Y; Tanaka N; Miyajima A; Mikami S; Oya M
    Ann Surg Oncol; 2016 Feb; 23(2):663-70. PubMed ID: 26350366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells.
    Matsui Y; Yamada T; Katayama Y; Hirai S; Sawada R; Tachibana Y; Ishida M; Kawachi H; Nakamura R; Nishioka N; Morimoto K; Iwasaku M; Horinaka M; Sakai T; Tokuda S; Takayama K
    Cancer Sci; 2024 Oct; 115(10):3333-3345. PubMed ID: 39039802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.